121 related articles for article (PubMed ID: 19171155)
1. The amplitudes of viral blips in HIV-1 infected patients treated with antiretroviral therapy are power-law distributed.
Percus JK; Percus OE; Di Mascio M
J Theor Biol; 2009 Apr; 257(3):454-9. PubMed ID: 19171155
[TBL] [Abstract][Full Text] [Related]
2. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
Di Mascio M; Ribeiro RM; Markowitz M; Ho DD; Perelson AS
Math Biosci; 2004; 188():47-62. PubMed ID: 14766093
[TBL] [Abstract][Full Text] [Related]
3. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy.
Percus JK; Percus OE; Markowitz M; Ho DD; Di Mascio M; Perelson AS
Bull Math Biol; 2003 Mar; 65(2):263-77. PubMed ID: 12675332
[TBL] [Abstract][Full Text] [Related]
4. Viral load assay sensitivity and low level viremia in HAART treated HIV patients.
Verhofstede C; Van Wanzeele F; Reynaerts J; Mangelschots M; Plum J; Fransen K
J Clin Virol; 2010 Apr; 47(4):335-9. PubMed ID: 20138803
[TBL] [Abstract][Full Text] [Related]
5. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
[TBL] [Abstract][Full Text] [Related]
6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.
Di Mascio M; Markowitz M; Louie M; Hurley A; Hogan C; Simon V; Follmann D; Ho DD; Perelson AS
J Virol; 2004 Oct; 78(19):10566-73. PubMed ID: 15367623
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 DNA and RNA kinetics in primary HIV infection.
Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
[TBL] [Abstract][Full Text] [Related]
9. Duration of an intermittent episode of viremia.
Di Mascio M; Percus JK; Percus OE; Markowitz M; Ho DD; Perelson AS
Bull Math Biol; 2005 Jul; 67(4):885-900. PubMed ID: 15893558
[TBL] [Abstract][Full Text] [Related]
10. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
11. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.
Macias J; Palomares JC; Mira JA; Torres MJ; García-García JA; Rodríquez JM; Vergera S; Pineda JA
J Infect; 2005 Oct; 51(3):195-200. PubMed ID: 16230215
[TBL] [Abstract][Full Text] [Related]
12. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
13. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
[TBL] [Abstract][Full Text] [Related]
14. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
15. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
16. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
17. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
[TBL] [Abstract][Full Text] [Related]
18. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
[TBL] [Abstract][Full Text] [Related]
19. How reliable is an undetectable viral load?
Combescure C; Vallier N; Ledergerber B; Cavassini M; Furrer H; Rauch A; Battegay M; Bernasconi E; Vernazza P; Hirschel B;
HIV Med; 2009 Sep; 10(8):470-6. PubMed ID: 19459990
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
Jones LE; Perelson AS
Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
